92 related articles for article (PubMed ID: 18990485)
1. EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts.
Newman JR; Helman EE; Safavy S; Zhang W; Rosenthal EL
Cancer Lett; 2009 Feb; 274(2):313-8. PubMed ID: 18990485
[TBL] [Abstract][Full Text] [Related]
2. Modulation of tumor cell growth in vivo by extracellular matrix metalloprotease inducer.
Newman JR; Bohannon IA; Zhang W; Skipper JB; Grizzle WE; Rosenthal EL
Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1218-24. PubMed ID: 19015455
[TBL] [Abstract][Full Text] [Related]
3. Extracellular matrix metalloprotease inducer stimulates fibroblast-mediated tumor growth in vivo.
Rosenthal EL; Vidrine DM; Zhang W
Laryngoscope; 2006 Jul; 116(7):1086-92. PubMed ID: 16826041
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells.
Liu Z; Hartman YE; Warram JM; Knowles JA; Sweeny L; Zhou T; Rosenthal EL
Mol Cancer Res; 2011 Aug; 9(8):1008-17. PubMed ID: 21665938
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Cao S; Durrani FA; Toth K; Rustum YM; Seshadri M
Oral Oncol; 2011 Jun; 47(6):459-66. PubMed ID: 21530364
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
[TBL] [Abstract][Full Text] [Related]
7. Cyclophilin A-EMMPRIN interaction induces invasion of head and neck squamous cell carcinoma.
Takahashi M; Suzuki S; Ishikawa K
Oncol Rep; 2012 Jan; 27(1):198-203. PubMed ID: 21956400
[TBL] [Abstract][Full Text] [Related]
8. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.
Bozec A; Etienne-Grimaldi MC; Fischel JL; Sudaka A; Toussan N; Formento P; Milano G
Oral Oncol; 2011 May; 47(5):340-4. PubMed ID: 21421338
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
10. Immunoexpression of EGFR and EMMPRIN in a series of cases of head and neck squamous cell carcinoma.
de Andrade AL; Ferreira SJ; Ferreira SM; Ribeiro CM; Freitas Rde A; Galvão HC
Pathol Res Pract; 2015 Oct; 211(10):776-81. PubMed ID: 26296920
[TBL] [Abstract][Full Text] [Related]
11. Expression and clinical significance of CD147 in genitourinary carcinomas.
Han ZD; He HC; Bi XC; Qin WJ; Dai QS; Zou J; Ye YK; Liang YX; Zeng GH; Zhu G; Chen ZN; Zhong WD
J Surg Res; 2010 May; 160(2):260-7. PubMed ID: 19286191
[TBL] [Abstract][Full Text] [Related]
12. Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147.
Newman JR; Gleysteen JP; Barañano CF; Bremser JR; Zhang W; Zinn KR; Rosenthal EL
Cancer Biol Ther; 2008 Jul; 7(7):1063-70. PubMed ID: 18431087
[TBL] [Abstract][Full Text] [Related]
13. Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer.
Dean NR; Newman JR; Helman EE; Zhang W; Safavy S; Weeks DM; Cunningham M; Snyder LA; Tang Y; Yan L; McNally LR; Buchsbaum DJ; Rosenthal EL
Clin Cancer Res; 2009 Jun; 15(12):4058-65. PubMed ID: 19509148
[TBL] [Abstract][Full Text] [Related]
14. Using intravital microscopy to observe bevacizumab-mediated anti-angiogenesis in human head and neck squamous cell carcinoma xenografts.
Yamatodani T; Holmqvist B; Kjellén E; Johnsson A; Mineta H; Wennerberg J
Acta Otolaryngol; 2012 Dec; 132(12):1324-33. PubMed ID: 23039202
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.
Kim H; Hartman YE; Zhai G; Chung TK; Korb ML; Beasley TM; Zhou T; Rosenthal EL
J Magn Reson Imaging; 2015 Oct; 42(4):936-45. PubMed ID: 25704985
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck.
Sauter ER; Nesbit M; Watson JC; Klein-Szanto A; Litwin S; Herlyn M
Clin Cancer Res; 1999 Apr; 5(4):775-82. PubMed ID: 10213212
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.
Skvortsova I; Skvortsov S; Raju U; Stasyk T; Riesterer O; Schottdorf EM; Popper BA; Schiestl B; Eichberger P; Debbage P; Neher A; Bonn GK; Huber LA; Milas L; Lukas P
Radiother Oncol; 2010 Jul; 96(1):108-15. PubMed ID: 20451273
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
19. Anti-EMMPRIN treatment of HNSCC in an ex vivo model.
Dean N; Helman E; Aldridge J; Carroll W; Magnuson S; Rosenthal E
Laryngoscope; 2010; 120 Suppl 4():S146. PubMed ID: 21225744
[No Abstract] [Full Text] [Related]
20. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
